Pharmacodynamics and pharmacokinetics of Veliten (rutine, alpha-tocopherol and ascorbic acid) in patients with chronic venous insufficiency.
The aim of this study was to evaluate the pharmacodynamics and pharmacokinetics of a single oral dose of Veliten in 12 patients affected by chronic venous insufficiency. In particular, the pharmacokinetics of two components of Veliten, namely rutine and alpha-tocopherol, were considered, while with respect to pharmacodynamics, studies were made of venous function, haemocoagulative and fibrinolytic balance, and haemorheological parameters. Correlation between such changes and plasma drug levels was also evaluated. We found a significant increase of venous tone, venous capacity and venous distension after drug intake, as well as a significant activation of fibrinolysis (globally evaluated with euglobulin lysis time), related to a slight increase of plasminogen tissue activator. These changes appeared concomitantly with maximal plasma levels of rutine. We did not find any modifications of coagulative and haemorheological parameters.
Auteri
A
A
Department of Immunology and Allergology, University of Siena, Italy.
Pasqui
A L
AL
Bruni
F
F
Di Renzo
M
M
Bova
G
G
Chiarion
C
C
Delchambre
J
J
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000925:Anticoagulants / Q000493:pharmacokinetics* / Q000494:pharmacology* / Q000627:therapeutic use; D001777:Blood Coagulation / Q000187:drug effects; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects; D006801:Humans; D006896:Hydroxyethylrutoside / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D010960:Plasminogen Activators / Q000097:blood; D013997:Time Factors; D014689:Venous Insufficiency / Q000097:blood / Q000188:drug therapy*; D014810:Vitamin E / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use
D000925:Anticoagulants; D006896:Hydroxyethylrutoside; D014810:Vitamin E; C005865:troxerutin; D010960:Plasminogen Activators